ReviewMolecular biology reports2022
Breast cancer in the era of precision medicine.
Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer.Frontiers in oncology · 2025Pooled it
- Association between hysterectomy for benign indications and the risk of breast cancer: a systematic review and meta- analysis.Frontiers in oncology · 2025Pooled it
- A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance.Current cancer drug targets · 2025Trial
- Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer.International journal of molecular sciences · 2026Article
- In Situ Gelling of TPZ-Loaded Nanogel for Sustained Intratumoral Delivery and Enhanced Cancer Immunotherapy.Gels (Basel, Switzerland) · 2026Article
- Review
- Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.Journal of clinical medicine · 2026Review
- An exosome-related gene signature predicts prognosis, immune suppression, and therapeutic sensitivity in luminal breast cancer.Discover oncology · 2026Article
- Improvements in Timely Care and Patient-Reported Outcomes for Breast Cancer: A Seven-Year Southern Brazilian Cohort Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Artificial intelligence for breast cancer management.Communications medicine · 2026Review
- Participant perceptions of the impact of the ModPad program on molecular diagnostic capacity building and public health practices.Frontiers in public health · 2026Article
- The Regulatory Mechanism and Value in Early Diagnosis and Prognosis Assessment of miR-4448 in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Multi-Scale Transcriptomic Sequencing Data Analysis RevealsOncology research · 2026Article
- Disorder of the immune and inflammatory response involving galectin-1, -3 and -7 in women with invasive breast cancer - potential importance in diagnosis and monitoring the course of the disease.Frontiers in oncology · 2026Article
- Gamma-aminobutyric acid affects the tumor microenvironment and angiogenesis, promoting breast cancer progression.CytoJournal · 2026Article
- Oleanolic acid and its derivatives in breast cancer therapy: mechanistic insights, structural modifications, and novel delivery strategies.Frontiers in pharmacology · 2026Review
- Value of Radiomics Based on DCE-MRI in distinguishing benign and malignant breast lesions: Predicting Histological Grade and Lymph Node Metastasis of Breast Cancer.Pakistan journal of medical sciences · 2026Article
- Review
- Digital integration of narrative medicine and patient-reported outcome measures to improve understanding of quality of life in metastatic breast cancer: the PERGIQUAL study.The oncologist · 2025Observational
- Comparison of clinicopathological features and survival in triple-negative and non-triple-negative breast cancer patients in Tanzania.The oncologist · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a heterogeneous disorder with different molecular subtypes and biological characteristics for which there are diverse therapeutic approaches and clinical outcomes specific to any molecular subtype. It is a global health concern due to a lack of efficient therapy regimens that might be used for all disease subtypes. Therefore, treatment customization for each patient depending on molecular characteristics should be considered. Precision medicine for breast cancer is an approach to diagnosis, treatment, and prevention of the disease that takes into consideration the patient's genetic makeup. Precision medicine provides the promise of highly individualized treatment, in which each individual breast cancer patient receives the most appropriate diagnostics and targeted therapies based on the genetic profile of cancer. The knowledge about the molecular features and development of breast cancer treatment approaches has increased, which led to the development of new targeted therapeutics. Tumor genomic profiling is the standard of care for breast cancer that could contribute to taking steps to better management of malignancies. It holds great promise for accurate prognostication, prediction of response to common systemic therapies, and individualized monitoring of the disease. The emergence of targeted treatment has significantly enhanced the survival of patients with breast cancer and contributed to reducing the economic costs of the health system. In this review, we summarized the therapeutic approaches associated with the molecular classification of breast cancer to help the best treatment selection specific to the target patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.